AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma
Stock Information for AVEO Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.